Core Insights - Neogen Corporation is set to release its first-quarter earnings results on October 9, with analysts expecting earnings of 4 cents per share, a decrease from 7 cents per share in the same period last year [1] - The company projects quarterly revenue of $204.15 million, down from $216.96 million a year earlier [1] - Neogen's shares fell by 7.1% to close at $5.63 on Monday [2] Analyst Ratings - William Blair analyst Brandon Vazquez downgraded Neogen's stock from Outperform to Market Perform on July 29, 2025, with an accuracy rate of 67% [7] - Guggenheim analyst Subbu Nambi maintained a Buy rating but reduced the price target from $13 to $10 on June 30, 2025, with an accuracy rate of 61% [7] - Piper Sandler analyst David Westenberg maintained a Neutral rating and lowered the price target from $6.4 to $5 on April 22, 2025, with an accuracy rate of 70% [7]

Core Insights - Neogen (NEOG) is expected to report quarterly earnings of $0.05 per share, a decline of 28.6% year-over-year, with revenues forecasted at $203.18 million, reflecting a decrease of 6.4% compared to the same period last year [1] Earnings Estimates - The consensus EPS estimate for the quarter has not changed over the past 30 days, indicating that analysts have not revised their initial projections [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Projections - Analysts predict specific revenue figures for Neogen's segments: - 'Revenues- Food Safety- Natural Toxins & Allergens' estimated at $18.68 million, down 8.3% year-over-year [5] - 'Revenues- Food Safety- Bacterial & General Sanitation' expected to reach $38.70 million, a decrease of 3% [5] - 'Revenues- Food Safety- Indicator Testing, Culture Media & Other' projected at $76.43 million, down 6.5% [6] - 'Revenues- Animal Safety- Veterinary Instruments & Disposables' forecasted at $13.94 million, an increase of 11.3% [6] - 'Revenues- Animal Safety- Animal Care & Other' expected to be $8.16 million, up 22.1% year-over-year [7] - 'Revenues- Food Safety' projected at $146.62 million, down 8% [7] - 'Revenues- Animal Safety- Genomics Services' estimated at $4.42 million, a significant decline of 72.2% [7] - 'Revenues- Food Safety- Genomics Services' expected at $13.26 million, a substantial increase of 137.3% [8] - 'Revenues- Animal Safety' forecasted at $54.65 million, down 5.2% year-over-year [8] Stock Performance - Neogen shares have increased by 5.4% over the past month, outperforming the Zacks S&P 500 composite, which rose by 4.3% [8] - Neogen holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market in the near term [8]

Core Viewpoint - Neogen (NEOG) is anticipated to report a year-over-year decline in earnings due to lower revenues, with the consensus outlook indicating potential impacts on its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on October 9, with a consensus EPS estimate of $0.05 per share, reflecting a year-over-year decrease of 28.6% [3][12]. - Revenues are projected to be $203.18 million, down 6.4% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 12.5% over the last 30 days, indicating a reassessment by analysts [4]. - Neogen's Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a positive reading being a strong predictor of an earnings beat [9][10]. - Neogen currently holds a Zacks Rank of 4, making it challenging to predict an earnings beat [12]. Historical Performance - In the last reported quarter, Neogen was expected to post earnings of $0.08 per share but only achieved $0.05, resulting in a surprise of -37.50% [13]. - The company has not beaten consensus EPS estimates in any of the last four quarters [14]. Conclusion - Neogen does not appear to be a compelling candidate for an earnings beat, and investors should consider other factors when evaluating the stock ahead of its earnings release [17].

Core Points - Neogen Corporation has renewed its commitment to the United States Equestrian Federation, extending a relationship that began in April 2024 [1] - Since joining US Equestrian, Neogen has provided support, resources, and educational tools to benefit the Federation and its members [1] - The renewed collaboration will focus on developing educational materials accessible to members [1]

Group 1 - Fred Alger Management's "Alger Weatherbie Specialized Growth Fund" reported a 10.94% gain for Q2 2025, with Class A shares outperforming the Russell 2500 Growth Index [1] - Initial market volatility in April was due to trade policy uncertainty following President Trump's tariffs, but stability returned with a 90-day pause on new duties [1] - Market sentiment improved in May after the White House suspended reciprocal tariff hikes on China, contributing to the S&P 500 reaching a record high in June [1] Group 2 - Neogen Corporation (NASDAQ:NEOG) focuses on food and animal safety, but its stock experienced a -2.44% return over the last month and a 65.98% decline over the past 52 weeks [2] - As of September 23, 2025, Neogen's stock closed at $5.60 per share, with a market capitalization of $1.217 billion [2] - Neogen's performance was negatively impacted by fiscal third-quarter revenue and profitability falling below expectations, leading to a modest reduction in full-year 2025 guidance due to a weaker macroeconomic environment [3] Group 3 - Neogen Corporation was held by 28 hedge fund portfolios at the end of Q2 2025, an increase from 15 in the previous quarter, indicating growing interest [4] - Despite the potential of Neogen as an investment, certain AI stocks are viewed as having greater upside potential and lower downside risk [4]

Core Points - Neogen Corporation will release its first-quarter earnings on October 9, 2025, before market opening [1] - A conference call and webcast will be held at 8:00 a.m. Eastern time on the same day to discuss the financial results [1] - Access to the conference call is available via a toll-free number for North America and an international dialing option [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Neogen Corporation common stock between January 5, 2023, and June 3, 2025, of the September 16, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Neogen common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by September 16, 2025, to serve as lead plaintiff [2] - The lawsuit alleges that Neogen's defendants made false and misleading statements about the integration process, leading investors to believe it was progressing smoothly [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in securities class action settlements [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]

Core Viewpoint - Neogen Corporation (NASDAQ: NEOG) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its integration with the Food Safety Division of 3M Company, which misled investors about the progress of the integration [3]. Group 1 - The class period for the lawsuit is from January 5, 2023, to June 3, 2025 [3]. - Allegations include that the defendants downplayed inefficiencies arising from the integration and assured investors of their commitment to resolving these issues quickly [3]. - Shareholders are encouraged to register for the class action by the deadline of September 16, 2025, to potentially become lead plaintiffs [4]. Group 2 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Group 1 - The article highlights a securities fraud class action lawsuit against Neogen Corporation, reminding investors of the September 16, 2025 deadline to participate as lead plaintiffs [1] - The lawsuit is on behalf of investors who acquired Neogen Corporation common stock between January 5, 2023, and June 3, 2025, inclusive [1] - Investors who lost money on Neogen Corporation are encouraged to participate in the lawsuit [1]

Core Viewpoint - Neogen Corporation (NASDAQ: NEOG) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its integration with the Food Safety Division of 3M Company, which misled investors about the progress of the integration [1]. Group 1: Allegations and Class Action Details - The class period for the lawsuit is from January 5, 2023, to June 3, 2025 [1]. - Defendants allegedly downplayed inefficiencies that arose during the integration process and assured investors of their commitment to resolving these issues quickly [1]. - Shareholders are encouraged to register for the class action and can do so without any cost or obligation [2]. Group 2: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].